Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
about
The Quest for Targets Executing MYC-Dependent Cell TransformationInhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiationDown-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue SarcomaKRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.Targeting MYC Dependence by Metabolic Inhibitors in CancerBitterness in sugar: O-GlcNAcylation aggravates pre-B acute lymphocytic leukemia through glycolysis via the PI3K/Akt/c-Myc pathway.Erythropoietin drives breast cancer progression by activation of its receptor EPORResponse of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.Distinct Transcriptomic Features are Associated with Transitional and Mature B-Cell Populations in the Mouse Spleen.Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation.β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.Processing Oscillatory Signals by Incoherent Feedforward Loops.Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective.Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cellsGas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.Modulation of formation of the 3'-end of the human argininosuccinate synthetase mRNA by GT-repeat polymorphism.The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer.miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.Infection by Toxoplasma gondii specifically induces host c-Myc and the genes this pivotal transcription factor regulates.Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma.Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.Parallel Expression of Enzyme Inhibitors of CD8T Cell Activity in Tumor Microenvironments and Secretory Endometrium.Drug-induced amino acid deprivation as strategy for cancer therapy.ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.Arginine dependence of tumor cells: targeting a chink in cancer's armor.The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.Three-dimensional environment renders cancer cells profoundly less susceptible to a single amino acid starvation.Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression.PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration.High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.Ultrasound-induced microbubble destruction promotes targeted delivery of adipose-derived stem cells to improve hind-limb ischemia of diabetic mice.A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.The PI3K/AKT/c-MYC Axis Promotes the Acquisition of Cancer Stem-Like Features in Esophageal Squamous Cell Carcinoma.Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.
P2860
Q26744579-A667378C-F3D5-41DE-8A69-45053BFF3AEDQ28542016-AE18D151-0323-4069-8246-504328A68E57Q28552369-2266CB10-306C-425D-87EB-9097BD751F46Q33566777-307979FC-D898-42DA-AAF3-7E73D51D96FDQ33608493-6F1366D5-536A-4132-A920-950ACD4D7D44Q33850060-0A85F042-8430-4C0D-8AA5-387002EF8942Q33888764-5F4C0647-33DB-4D6F-B87C-2525568BA016Q33946905-C9FEAE57-56B6-441B-A8FE-FC6DE3704E99Q34600157-F5B14D08-2991-4143-8E44-336D9821419AQ35071862-7072322A-16E5-4317-B91A-293E3DCB9AE2Q35072584-ED6B0429-503B-4731-B6A9-6F1EA13C8471Q35137658-E815E14A-E742-4CA0-A7AB-1D0F6911F8F5Q36121733-35E639F0-E4E3-4CF5-AB87-2AD7C087E1DCQ36131481-32C67367-0F3F-4D3D-A5A2-4FBC2A205D04Q36271522-FB555B34-CF59-45CD-81CE-07537955348CQ36356248-1D0DE4A0-5403-4C11-A1B3-4AAE0034F973Q36808017-537C1F01-FBAE-4C83-97AB-71990C58F0F1Q37109564-88B11F6D-741F-4993-89A0-0424F3638876Q37339881-7D7C56E3-D60F-48F9-B353-3DFCF5CB2638Q37402559-12D02C6B-1B37-4931-B1FC-FC32AE1D3BE6Q37494267-6F89161A-DEB8-4416-92B2-1276685A2F4CQ37590529-B4885AC1-94A2-43C3-9D61-3A82177F7372Q37696195-0E60E9C5-EA11-46A3-BC47-706EFC89A73BQ37723997-DD5F24C0-11B6-4130-9665-5D53B9C104EEQ38030652-ABD7BE4D-A942-4DF6-B603-A36B4741CA8AQ38181070-FAA37421-D497-4B45-B1E7-E8B1BEC6CABEQ38579710-308C4A0A-72AC-4AD0-A0AB-38D645F9105CQ38657061-DAB8F892-A3BF-43B7-AF5C-57B0F66BD1BFQ38729065-5F4F1C40-0234-4E61-B621-045969777C66Q38816145-43ED038B-6133-4139-8CC9-F0486B2AA6D6Q39030462-A8C47B79-013C-4B57-A290-316C42BE137FQ39084498-A8802316-25D5-4E27-AAF2-69981175127AQ39095939-86733B46-17D2-497E-96A9-84C208753065Q41534994-1BCA74B7-13C1-437E-82C1-AF542038CA28Q41708842-6146F9F5-ED42-4ABE-BED6-C2C0CCDC4227Q41830810-50C1F828-DD94-467A-8679-B377EB0A72A1Q42068597-8B137E99-45BE-44B5-BD63-4821FC83D87AQ43601788-9560417F-6FF9-4BEC-A831-16763D89699EQ46553742-3B80AA7E-5720-4CFD-A3B9-FF17F2C9768EQ47097618-F6B7A276-4749-4E84-9324-7B8584695172
P2860
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Activation of Ras/PI3K/ERK pat ...... resistance in melanoma cells.
@ast
Activation of Ras/PI3K/ERK pat ...... resistance in melanoma cells.
@en
type
label
Activation of Ras/PI3K/ERK pat ...... resistance in melanoma cells.
@ast
Activation of Ras/PI3K/ERK pat ...... resistance in melanoma cells.
@en
prefLabel
Activation of Ras/PI3K/ERK pat ...... resistance in melanoma cells.
@ast
Activation of Ras/PI3K/ERK pat ...... resistance in melanoma cells.
@en
P2093
P2860
P1433
P1476
Activation of Ras/PI3K/ERK pat ...... resistance in melanoma cells.
@en
P2093
Hui-Kuan Lin
Isamu Aiba
Macus Tien Kuo
Niramol Savaraj
Wen-Bin Tsai
P2860
P304
P356
10.1158/0008-5472.CAN-11-3605
P407
P577
2012-03-29T00:00:00Z